A recent study demonstrated that combinatorial treatment of a c-Met and ERBB inhibitor (capmatinib and afatinib) abolished tumor growth in NSCLC brain metastasis mouse models with MET amplification conferring acquired resistance to osimertinib [83]. This evidence concerns the gene MET and neoplasm.